Boehringer Ingelheim expands oncology portfolio with T3 Pharma acquisition
Boehringer Ingelheim announced its acquisition of T3 Pharmaceuticals AG (“T3 Pharma”), a Swiss biotech company specializing in immuno-oncology, for up to 450 million CHF. T3 ... Read More
FDA approves AstraZeneca’s Truqap for advanced breast cancer treatment
In a notable development in the field of oncology, the US Food and Drug Administration (FDA) has approved AstraZeneca’s Truqap (capivasertib) in combination with Faslodex ... Read More
ValiRx and StingRay Bio collaborate on preclinical cancer therapeutics research
ValiRx Plc (AIM: VAL), a pioneering life science company, has entered into a strategic agreement with StingRay Bio Limited to evaluate a series of drug ... Read More
Crown Bioscience launches OrganoidXplore: A game-changer for preclinical oncology research
Leading global contract research organization, Crown Bioscience, has unveiled OrganoidXplore, a trailblazing service offering in the domain of preclinical oncology research. This state-of-the-art platform promises ... Read More
Galapagos NV taps Landmark Bio for CAR-T therapy production
Landmark Bio has entered into a pivotal strategic manufacturing agreement with Galapagos NV, signaling a notable advance in the field of genomic medicines. This multi-year ... Read More
Merck strikes €1.4bn deal with Hengrui Pharmaceuticals for next-gen oncology treatments
In a major advancement in cancer treatment, Merck, a frontrunner in science and technology, has declared a strategic collaboration with Jiangsu Hengrui Pharmaceuticals Co. Ltd. ... Read More
Bristol Myers Squibb to acquire Mirati Therapeutics in $4.8bn deal
Bristol Myers Squibb (NYSE: BMY) is set to acquire Mirati Therapeutics, Inc. (NASDAQ: MRTX) at $58.00 per share in a cash deal valued at $4.8 ... Read More
Venus Remedies expands cancer drug portfolio in South Eastern Europe
In a significant development for its oncology portfolio in South Eastern Europe, Venus Remedies Ltd has been granted marketing authorization from Serbia for chemotherapy drugs ... Read More
Enhertu shows promising results in DESTINY-PanTumor02 Phase 2 trial
The DESTINY-PanTumor02 Phase II trial revealed high-level results for AstraZeneca and Daiichi Sankyo’s Enhertu (trastuzumab deruxtecan), showcasing clinically meaningful progression-free survival (PFS) and overall survival ... Read More
Gilead’s Trodelvy gains EC approval as new hope for metastatic breast cancer patients
In a significant advancement for cancer treatment, the European Commission (EC) has approved Gilead Sciences' Trodelvy (sacituzumab govitecan) for the treatment of adult patients suffering ... Read More